Tag:
Ipsogen
Latest Headlines
Latest Headlines
Qiagen amends offer for Cellestis, provides update on Ipsogen
Qiagen has amended its original proposal to acquire Australia's Cellestis, increasing its per-share offer price to A$3.80 ($4.06) from the original offer price of A$3.55 ($3.79). The amended...
Q&A with QIAGEN about Ipsogen buy
Recently, QIAGEN announced it has entered into talks to purchase a 47 percent initial stake in France's Ipsogen and subsequently make a public offer to fully acquire the company. The potential
QIAGEN looks to buy Ipsogen
QIAGEN has entered into talks to purchase a 47 percent initial stake in France's Ipsogen and subsequently make a public offer to fully acquire the company. The potential acquisition would give QIAGEN
